Cargando…

Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

Biomarkers for optimizing the outcome of treatment with lenvatinib in patients with advanced hepatocellular carcinoma remain to be established despite intensive and comprehensive genomic research. Lenvatinib is characterized by its prominent inhibitory potency for fibroblast growth factor receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamauchi, Masami, Ono, Atsushi, Ishikawa, Akira, Kodama, Kenichiro, Uchikawa, Shinsuke, Hatooka, Haruna, Zhang, Peiyi, Teraoka, Yuji, Morio, Kei, Fujino, Hatsue, Nakahara, Takashi, Murakami, Eisuke, Miki, Daiki, Kawaoka, Tomokazu, Tsuge, Masataka, Hiramatsu, Akira, Imamura, Michio, Hayes, Clair Nelson, Fujita, Masashi, Nakagawa, Hidewaki, Yasui, Wataru, Aikata, Hiroshi, Chayama, Kazuaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7263646/ https://www.ncbi.nlm.nih.gov/pubmed/32677805 http://dx.doi.org/10.14309/ctg.0000000000000179

Ejemplares similares

Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy
por: Ohya, Kazuki, et al.
Publicado: (2019)

Early experience of seven hepatocellular carcinoma cases treated with regorafenib
por: Uchikawa, Shinsuke, et al.
Publicado: (2018)

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib
por: Fujii, Yasutoshi, et al.
Publicado: (2021)

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib
por: Ono, Atsushi, et al.
Publicado: (2020)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma
por: Yamauchi, Masami, et al.
Publicado: (2023)

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis
por: Fujino, Hatsue, et al.
Publicado: (2019)

Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection
por: Ohya, Kazuki, et al.
Publicado: (2019)

Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study
por: Nagaoki, Yuko, et al.
Publicado: (2021)

A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system
por: Yoshikawa, Yuki, et al.
Publicado: (2021)

In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism
por: Liu, Songyao, et al.
Publicado: (2021)

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy
por: Nagaoki, Yuko, et al.
Publicado: (2017)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment
por: Tamura, Yosuke, et al.
Publicado: (2023)

Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection
por: Ueda, Naoyuki, et al.
Publicado: (2020)

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment
por: Yamaoka, Kenji, et al.
Publicado: (2022)

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures
por: Nishida, Yuno, et al.
Publicado: (2020)

Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib
por: Yamaoka, Kenji, et al.
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial
por: Hatooka, Masahiro, et al.
Publicado: (2018)

Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring
por: Honda, Fumi, et al.
Publicado: (2018)

Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients
por: Murakami, Eisuke, et al.
Publicado: (2021)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021)

Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene
por: Miura, Ryoichi, et al.
Publicado: (2022)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
por: Johira, Yusuke, et al.
Publicado: (2023)

Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices
por: Shirane, Yuki, et al.
Publicado: (2022)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
por: Kinami, Takahiro, et al.
Publicado: (2023)

Impact of skeletal muscle volume on patients with BCLC stage‐B hepatocellular carcinoma undergoing sorafenib therapy
por: Saeki, Issei, et al.
Publicado: (2023)

Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma
por: Saeki, Issei, et al.
Publicado: (2021)

Management of Systemic Therapies and Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma Based on Sarcopenia Assessment
por: Yamasaki, Takahiro, et al.
Publicado: (2022)

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions
por: Yano, Shigeki, et al.
Publicado: (2023)

Efficacy and safety of chemoradiation therapy using one-shot cisplatin via hepatic arterial infusion for advanced hepatocellular carcinoma with major macrovascular invasion: a single-arm retrospective cohort study
por: Naruto, Kensuke, et al.
Publicado: (2022)

Migration to the pulmonary artery of nine metallic coils placed in the internal iliac vein for treatment of giant rectal varices
por: Yamasaki, Wataru, et al.
Publicado: (2012)

Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle
por: Hayes, C. Nelson, et al.
Publicado: (2012)

Efficacy and safety of lenvatinib–transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study
por: Oshita, Ko, et al.
Publicado: (2023)

Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy
por: Ono, Atsushi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_diapt0td01nalb29epg794b4if